3.62%
3.05%
-45.86%
-54.21%
-41.32%
-82.25%
-93.15%
AI Spotlight on LVTX
Company Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies.LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc.for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use.
The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Market Data
| Last Price | 0.98 |
| Change Percentage | 3.62% |
| Open | 0.96 |
| Previous Close | 0.95 |
| Market Cap ( Millions) | 26 |
| Volume | 26827 |
| Year High | 6.47 |
| Year Low | 0.88 |
| M A 50 | 1.23 |
| M A 200 | 1.87 |
Financial Ratios
| FCF Yield | -109.73% |
| Dividend Yield | 0.00% |
| ROE | -62.22% |
| Debt / Equity | 19.06% |
| Net Debt / EBIDTA | 75.50% |
| Price To Book | 0.8 |
| Price Earnings Ratio | -0.95 |
| Price To FCF | -0.91 |
| Price To sales | 3.51 |
| EV / EBITDA | -0.19 |
News
- Jan -10 - LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
- Dec -10 - LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
- Sep -03 - LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Aug -20 - LAVA Reports Second Quarter 2024 Financial Results and Business Update
- Aug -08 - 4 Stocks Under $5 To Buy Now
- Jul -22 - All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy
- Jun -20 - LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Jun -10 - LAVA Announces Annual Meeting of Shareholders
- May -30 - LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
- May -21 - LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
- May -06 - LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
- Mar -20 - LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- Mar -05 - LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
- Jan -25 - LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
- Nov -16 - Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- Sep -06 - LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Aug -22 - LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates
- Aug -22 - LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
- Aug -14 - LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
- Jun -15 - Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Bispecific Antibodies
Expected Growth : 11.3 %
What the company do ?
Novel Bispecific Antibodies from LAVA Therapeutics N.V. are engineered to redirect T cells to target cancer cells, enhancing anti-tumor responses and improving treatment outcomes.
Why we expect these perspectives ?
LAVA Therapeutics N.V.'s novel bispecific antibodies drive 11.3% growth, fueled by increasing demand for targeted cancer therapies, advancements in antibody engineering, and strategic partnerships. Additionally, expanding pipeline of candidates, growing prevalence of cancer, and rising healthcare expenditure contribute to the segment's rapid expansion.
Lava Therapeutics N.V. Products
| Product Range | What is it ? |
|---|---|
| Gamma-Delta T Cell Engagers | LAVA Therapeutics N.V. develops gamma-delta T cell engagers, a novel class of bispecific antibodies that selectively target and activate gamma-delta T cells for the treatment of various types of cancer. |
| LAVA-051 | LAVA-051 is a gamma-delta T cell engager that targets CD1d, a protein expressed on the surface of certain cancer cells, and activates gamma-delta T cells to kill these cells. |
| LAVA-1207 | LAVA-1207 is a gamma-delta T cell engager that targets a tumor-specific antigen and activates gamma-delta T cells to kill cancer cells. |
LAVA Therapeutics N.V.'s Porter Forces
Threat Of Substitutes
LAVA Therapeutics N.V. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
LAVA Therapeutics N.V. has a diverse customer base, and no single customer has significant bargaining power, reducing the threat of customer bargaining power.
Bargaining Power Of Suppliers
LAVA Therapeutics N.V. relies on a few key suppliers for raw materials and equipment, giving them some bargaining power, but the company's strong relationships with suppliers mitigate this threat.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market, posing a significant threat to LAVA Therapeutics N.V.'s market share.
Intensity Of Rivalry
The biotechnology industry is highly competitive, and LAVA Therapeutics N.V. faces intense rivalry from established companies and new entrants, making it challenging to maintain market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 10.98% |
| Debt Cost | 3.95% |
| Equity Weight | 89.02% |
| Equity Cost | 7.35% |
| WACC | 6.97% |
| Leverage | 12.34% |
LAVA Therapeutics N.V. : Quality Control
LAVA Therapeutics N.V. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHM.MC | Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest … |
| CALTX.ST | Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It … |
| PRQR | ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III … |
| NAMS | NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets … |
| ATAI | Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharma Mar
A-Score
1-Year Total Return ->
🥈
Calliditas Therapeutics
A-Score
1-Year Total Return ->
🥉
ProQR Therapeutics
A-Score
1-Year Total Return ->
4
LAVA Therapeutics
A-Score
1-Year Total Return ->
5
NewAmsterdam Pharma
A-Score
1-Year Total Return ->
6
